Cardiovascular Events Associated with CDK4/6 Inhibitors: A Safety Meta-Analysis of Randomized Controlled Trials and a Pharmacovigilance Study of the FAERS Database
- 18 December 2024
- journal article
- research article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 25 (3) , 373-388
Abstract
Background CDK4/6 inhibitors are highly valued, but the incidence of cardiovascular adverse events (CVAEs) associated with CDK4/6 inhibitors is not clear. Objective Our aim was therefore to assess the risk of developing CVAEs associated with CDK4/6 inhibitors, by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs), along with a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS) database. Methods Eligible CVAEs were extracted from the ClinicalTrials.gov registry. A systematic search of electronic databases (PubMed, Embase, Cochrane Library, and important meetings) until 3 September 2023 was conducted. A disproportionality analysis was performed from the first quarter (Q1) of 2013 to Q1 of 2023 using data from the FAERS database. Study heterogeneity was assessed using the I2 statistic. Using Peto odds ratio (Peto OR) and inverse variance methods to calculate the risk and incidence of CVAEs associated with CDK4/6 inhibitors. Results In total, 17 RCTs with 23,437 patients were included in our meta-analysis. During the follow-up period of 8.4–34.0 months, CDK4/6 inhibitors significantly increased the risk of CVAEs (Peto OR, 1.86, 95% confidence interval, 1.30–2.68, P < 0.01). The rates of hypertension and QT prolongation were 68.07 (62.87–73.27) and 57.15 (50.83–63.48) per 1000 patients, respectively. Moreover, we identified nine CVAEs that were not reported in RCTs. These included acute coronary syndrome, arrhythmia, lymphoedema, hot flush, vein rupture, thrombophlebitis migrans, embolism venous, angiopathy and intracardiac thrombus, which were found to be strongly correlated with CDK4/6 inhibitors. Furthermore, the risk of CVAEs varied depending on the specific CDK4/6 inhibitors used, its combination with different endocrine therapies, and the patient's treatment stage. Conclusion CDK4/6 inhibitors increase the risk of CVAEs, some of which may lead to serious consequences. Early recognition and management of CVAEs is of great importance in clinical practice. Registration PROSPERO registration number CRD42023462059.Keywords
Funding Information
- The National Natural Science Foundation of China (82160859)
- Program for Top 100 Innovative Talents in Colleges and Universities of Hebei Province (--)
This publication has 45 references indexed in Scilit:
- Beyond clinical trials: CDK4/6 inhibitor efficacy predictors and nomogram model from real‐world evidence in metastatic breast cancerCancer Innovation, 2024
- Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directionsBiomedicine & Pharmacotherapy, 2023
- Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant ChemotherapyJAMA Oncology, 2022
- Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trialsThe Breast, 2022
- Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3The Oncologist, 2020
- Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trialsBreast Cancer Research and Treatment, 2020
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsAnnals of Oncology, 2020
- Different Cardiotoxicity of Palbociclib and Ribociclib in Breast Cancer: Gene Expression and Pharmacological Data Analyses, Biological Basis, and Therapeutic ImplicationsBioDrugs, 2019
- Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trialBreast Cancer Research and Treatment, 2017
- The fractions of cancer attributable to modifiable factors: A global reviewCancer Epidemiology, 2016